91������Ʒ

(WASHINGTON, October 26, 2023) – Today, the 91������Ʒ (ASH), the world’s largest professional society focused on advancing the field of blood disorders, announced the election of three new members to its Executive Committee for terms starting after the 2023 ASH Annual Meeting, December 9-12, 2023, in San Diego, California. 

Robert S. Negrin, MD, will serve a one-year term as vice president followed by successive terms as president-elect and president. Mary M. Horowitz, MD, MS, and H. Leighton Grimes, PhD, will serve four-year terms as councillors. Dr. Grimes will serve as ASH’s first-ever Councillor in Basic Investigative Research, a designated position for a PhD (or equivalent) scientist to ensure that the interests of the scientific community are appropriately represented on the Executive Committee.

"Drs. Negrin, Horowitz, and Grimes have demonstrated immense dedication to ASH, its members, and the field of hematology. Together, they represent the future of the Society and the field. I congratulate them on the results of the election, and I look forward to hearing the unique perspectives and insights they’ll bring to the Society,” said current ASH President, Robert A. Brodsky, MD, of Johns Hopkins University School of Medicine. “Under their leadership, the Society will be well-positioned to lead our field in education, cutting-edge research, and advocacy on behalf of patients with blood disorders worldwide."

Dr. Negrin, vice president-elect, is professor of medicine at Stanford University. As a distinguished physician-scientist, Dr. Negrin has made significant research contributions in the areas of hematopoietic cell transplantation, cellular immunology, and immune system regulation. He is also deeply committed to training the next generation of physicians and scientists.

Dr. Negrin has demonstrated a deep devotion to ASH’s mission through roughly 25 years of service on a range of ASH committees and working groups. An ASH member since 1998, Dr. Negrin most recently served as the founding editor-in-chief of (2016-2021), an open access, online-only publication that has grown to publish more peer-reviewed hematology research than any other academic journal worldwide.

"In this extraordinary time in hematology, I look forward to working with the Society to strengthen the hematology workforce, support innovative research, and promote access to existing and emerging therapies for patients with hematologic disorders. I am honored to have the opportunity to lead such a highly regarded society and serve the global hematology community,” said Dr. Negrin.

Dr. Horowitz, councillor-elect, is deputy director of the Medical College of Wisconsin Cancer Center. Her research interests include hematopoietic stem cell transplantation, survivorship and quality of life, and the integration of real-world and clinical trial data. Dr. Horowitz has been a member of ASH since 1981. She was previously chair of the Nominating Committee (2019-2022) and was co-founder of the ASH-CIBMTR-ASTCT Minority Career Development Award.

Dr. Grimes, Basic Investigative Research Councillor-elect, is professor in the division of immunobiology at Cincinnati Children’s Hospital Medical Center. His research background is in hematopoiesis, molecular biology, and molecular oncology, including mouse modeling of hematopoiesis, myelopoiesis, and marrow failure syndromes. His work focuses on myelodysplastic syndromes, severe congenital neutropenia, and acute myeloid leukemia. An active ASH member since 2001, Dr. Grimes has been a member of the Awards Committee, an ad hoc member of the Scientific Committee on Bone Marrow Failure, and chair of the Scientific Committee on Myeloid Biology.

The 91������Ʒ (ASH) (hematology.org) is the world’s largest professional society of hematologists dedicated to furthering the understanding, diagnosis, treatment, and prevention of disorders affecting the blood. For more than 60 years, the Society has led the development of hematology as a discipline by promoting research, patient care, education, training, and advocacy in hematology.

ASH’s flagship journal, Blood () is the most cited peer-reviewed publication in the field, and Blood Advances () is an open-access, online journal that publishes more peer-reviewed hematology research than any other academic journal worldwide. Two new journals will be joining the Blood Journals portfolio in 2024, Blood Neoplasia () and Blood Vessels, Thrombosis & Hemostasis ().

Contact:  
Kira Sampson, 91������Ʒ  
[email protected]; 202-499-1796